Current price is less than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Themis Medicare consolidated net profit declines 44.23% in the June 2022 quarter

VIRALEX (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties.

Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

Themis Medicare rose 3.37% to Rs 857.80 after the company announced the add on approval for drug “Viralex” by the Drug Controller General of India (DCGI).

Themis Medicare climbs after Viralex gets add on approval from DCGI

Mumbai-based pharmaceutical company Themis Medicares anti-viral drug Viralex has received Drugs Controller General of Indias (DCGI) approval, the company informed the stock exchange on Monday.

Themis Medicare’s anti-viral COVID drug gets DCGI nod

Enhances both innate & adaptive immunity and strengthens body’s immune response to viral infections In a landmark development for the treatment of COVID-19, Themis Medicare Ltd. (Themis), - Mediawire

Themis gets Drug Controller’s nod to launch Inosine Pranobex a novel medicine to treat Covid19, A Viral Infection

STOCKS TO WATCH: Vodafone Idea, SJVN, Wockhardt, John Cockerill, Themis Medicare, IndiaMart, LT Foods, Eveready Industries

Stocks that will see action today (March 4)

Themis Medicare Consolidated December 2021 Net Sales at Rs 94.92 crore, up 44.88% Y-o-Y

Themis Medicare on Friday announced that it received approval from Drug Controller General of India (DCGI) for its antiviral drug VIRALEX.

Themis Medicare receives approval for COVID drug from DCGI

The new Subsidiary Company was incorporated under the Companies Act 2006 as a private Company.

Themis Medicare incorporates new subsidiary company ‘Carpo Investments’

Continued improvement in TML’s financial risk profile will continue to remain a rating sensitivity factor.

Acuite rates Themis Medicare’s bank loan facilities at ‘BBB-/Stable’

Themis Medicare Ltd has added 15.75% over last one month compared to 3.56% fall in S&P BSE Healthcare index and 0.26% drop in the SENSEX

Themis Medicare Ltd Surges 3.83%

Themis Medicare Limited is engaged in manufacturing pharmaceuticals and medicinal chemicals, such as formulations and active pharmaceutical ingredients.

Themis Medicare Ltd

Themis Medicare Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Themis Medicare consolidated net profit declines 44.23% in the June 2022 quarter

Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

Themis Medicare climbs after Viralex gets add on approval from DCGI

Themis Medicare’s anti-viral COVID drug gets DCGI nod

Themis gets Drug Controller’s nod to launch Inosine Pranobex a novel medicine to treat Covid19, A Viral Infection

Stocks that will see action today (March 4)

Themis Medicare Consolidated December 2021 Net Sales at Rs 94.92 crore, up 44.88% Y-o-Y

Themis Medicare Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Themis Medicare consolidated net profit declines 44.23% in the June 2022 quarter

Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

Themis Medicare climbs after Viralex gets add on approval from DCGI

Themis Medicare’s anti-viral COVID drug gets DCGI nod

Themis gets Drug Controller’s nod to launch Inosine Pranobex a novel medicine to treat Covid19, A Viral Infection

Stocks that will see action today (March 4)

Themis Medicare Consolidated December 2021 Net Sales at Rs 94.92 crore, up 44.88% Y-o-Y

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock